|
| U.S. Brand Names |
| Orimune® |
 |
| Generic Available |
|
No |
|
| Synonyms |
| OPV; Sabin Vaccine; TOPV |
|
| Pharmacological Index |
|
Vaccine |
|
| Use |
|
Poliovirus immunization |
|
| Pregnancy Risk Factor |
|
C |
|
| Adverse Reactions |
|
All serious adverse reactions must be reported to the Vaccine Adverse Event Reporting System (1-800-822-7967) |
|
| Stability |
|
Keep in freezer; vaccine must remain frozen to retain potency |
|
| Usual Dosage |
|
Oral: Older Children, Adolescents, and Adults: Two 0.5 mL doses 8 weeks apart; third dose of 0.5 mL 6-12 months after second dose; a reinforcing dose of 0.5 mL should be given before entry to school, in children who received the third primary dose before their fourth birthday |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Patient Information |
|
Because of the risk of vaccine-associated paralysis, unvaccinated family members and close personal contacts should be vaccinated prior to the child |
|
| Nursing Implications |
|
Do not administer parenterally; administer directly or dilute with distilled water, simple syrup USP, or milk; may be administered on bread or sugar cubes |
|
| Dosage Forms |
|
Solution, oral: Mixture of type 1, 2, and 3 viruses in monkey kidney tissue (0.5 mL) |
|
|
Copyright © 2007 Drugs Area |
